May 14, 5:05 PMPrecipio reports Q1 2026 results with revenue of $6.71 million, adjusted EBITDA of negative $0.16 million, and positive operating cash flow of $60,000.
Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. It operates through the following business divisions: Pathology Services and Products. The Pathology Services division provides specialized cancer diagnostic testing services to physicians, hospitals, and laboratories. The Products divisions develops and commercializes proprietary assays designed for use by clinical laboratories. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.
FounderMr. Ilan Danieli
Chief Operating OfficerMr. Ahmed Zaki Sabet
Chief Technology OfficerDr. Ayman A. Mohamed M.D.
Chief Financial OfficerMr. Matthew Gage
Chief Legal Counsel & People OfficerMs. Miri Chiko-Radomski
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, alerts, and much more.